USFDA classifies Aurobindo Pharma Inc's warehouse as OAI
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
The USFDA has determined the inspection classification status of this warehousing facility as 'Official Action Indicated
Growth markets revenue increased by 44 YoY to Rs. 812 crore
USFDA completes PAI of Lupin’s biotech facility in Pune
The product is expected to be launched in Q3FY25
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
The approved product has an estimated market size of US$ 268 million for the twelve months ending June 2024, according to IQVIA
Ace Lab conducts 170 batches of testing per month and has capacity to do more than 250 batches per month
Lupin updates on shipment of Mirabegron ER Tablets
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
Subscribe To Our Newsletter & Stay Updated